For decades, the United States has led the world in pharmaceutical innovation – developing drugs that combat cancer, heart ...

Novo Nordisk (NVO) released clinical trial results for its potential Ozempic successor on Monday, disappointing Wall Street for the second time. The pharmaceutical giant, known for its blockbuster ...

Novo Nordisk shares rose Monday as the company said it would present new data on the ability of semaglutide, the active ...

Novo Nordisk is rolling out a new national marketing campaign for its GLP-1 juggernaut, teaming up with celebrities and other patients to show what life looks like in their “Ozempic Eras.” ...

Novo Nordisk released the results from its late-stage trial of CagriSema on Monday. It showed that patients on the highest ...

PLAINSBORO, N.J., March 3, 2025 /PRNewswire/ -- Novo Nordisk launched "My Ozempic ® Era" today, a national campaign which spotlights the longstanding Ozempic ® patient community by sharing ...

Novo Nordisk (NVO) released clinical trial results for its potential Ozempic successor on Monday, disappointing Wall Street ...

Novo Nordisk (NVO) ended a five-day losing streak ... rating on the maker of hugely popular obesity/ diabetes drugs, Ozempic and Wegovy. Nine years after starting its coverage, the Paris-based ...

Novo Nordisk (NVO), the company behind popular diabetes and obesity treatments Ozempic and Wegovy, saw its stock rise on Thursday after ...

The Ozempic shortage is over and the Ozempic era is here. Novo Nordisk launched its latest campaign – My Ozempic Era – just a few weeks after the Food and Drug Administration took semaglutide, the ...